Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.57 |
| ▸ | CTSS | P25774 | 6/20 | 0.57 |
| ▸ | CTSB | P07858 | 6/20 | 0.57 |
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900827 | 0.93 | CTSL (0.63) | CTSLCTSSCTSBCTSKTACR1 | |
| SCHEMBL30117973 | 0.92 | CTSL (0.53) | CTSLCTSSCTSBCTSKTACR1 | |
| SCHEMBL9942953 | 0.90 | CTSL (0.49) | CTSLCTSSCTSBCTSKTACR1 | |
| SCHEMBL51465 | 0.90 | CTSL (0.49) | CTSLCTSSCTSBCTSKTACR1 | |
| SCHEMBL52449 | 0.90 | CTSS (0.52) | CTSLCTSSCTSBCTSK | |
| SCHEMBL2081142 | 0.87 | MEN1 (0.51) | CTSLCTSSCTSBCTSKSMN1; SMN2 | |
| SCHEMBL62133 | 0.87 | CTSS (0.49) | CTSLCTSSCTSBCTSKTACR1 | |
| SCHEMBL10556366 | 0.87 | CTSL (0.52) | CTSLCTSSCTSBCTSKLMNA | |
| SCHEMBL87370 | 0.86 | CTSS (0.51) | CTSLCTSSCTSBCTSKPREP | |
| SCHEMBL52043 | 0.86 | CTSS (0.48) | CTSLCTSSCTSBCTSKPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4584258-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12180193-B2 | Accelerating fibrosarcoma protein degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-12161625-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12156916-B2 | Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240156967-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240156968-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11957759-B1 | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2024054591-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| EP-2225238-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | Boehringer Ingelheim International GmbH (DE) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | HPGDS, COL14A1, ARG1 | CTSL 1057/4885CTSS 335/4885CTSB 1606/4885 |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | CTSL 1402/4885CTSS 638/4885CTSB 1256/4885 |
| US-12161625-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | CTSL 1324/4885CTSS 3150/4885CTSB 2201/4885 |
| US-12156916-B2 | Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | BRAF, ARAF, RAF1 | CTSL 2584/4885CTSS 2648/4885CTSB 3359/4885 |
| US-12180193-B2 | Accelerating fibrosarcoma protein degrading compounds and associated methods of use | CRBN, RBX1, ARAF | CTSL 2948/4885CTSS 2458/4885CTSB 2216/4885 |
| US-20240156968-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARAF, BRAF, HRAS | CTSL 2236/4885CTSS 1073/4885CTSB 895/4885 |
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | CTSL 2909/4885CTSS 2635/4885CTSB 2261/4885 |
| US-20240156967-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | BRAF, ARAF, RAF1 | CTSL 2700/4885CTSS 2772/4885CTSB 3408/4885 |
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARAF, BRAF, HRAS | CTSL 2236/4885CTSS 1073/4885CTSB 895/4885 |
| US-11957759-B1 | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | BRAF, ARAF, RAF1 | CTSL 2756/4885CTSS 2771/4885CTSB 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.